Side-by-Side Comparison
Thymosin Alpha-1 vs TB-500: Mechanism, Evidence & Safety Compared
An evidence-based side-by-side look at how Thymosin Alpha-1 and TB-500 differ in mechanism, regulatory status, strength of the research base, and clinical application — compiled from the published literature and the FDA regulatory record.
Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.
Also: Tα1, Thymalfasin, Zadaxin
A naturally occurring thymic peptide approved internationally for immune modulation, with extensive clinical data in hepatitis and cancer immunotherapy.
TB-500
L3Also: Thymosin Beta-4, TB4, Tβ4
A naturally occurring peptide central to cell migration and tissue repair. Phase 2 human wound healing trials showed accelerated healing; also studied for cardiac and corneal repair.
Side-by-side comparison
| Attribute | Thymosin Alpha-1 | TB-500 |
|---|---|---|
| Primary mechanism | Dendritic Cell & T-Cell Activation | Actin Sequestration & Cell Migration |
| FDA status | Research Only | Banned from Compounding (Category 2) |
| Evidence level | Strong Clinical Evidence | Emerging Clinical Evidence |
| Human trials | Yes (30+ indexed) | Yes (3+ indexed) |
| Studies indexed | 113 total (45 human, 30 animal) | 119 total (4 human, 85 animal) |
| Primary uses researched | Immune modulation, Hepatitis B treatment, Cancer immunotherapy adjuvant, Vaccine enhancement | Wound healing, Tissue repair, Anti-inflammatory, Hair growth |
| Administration routes | subcutaneous | subcutaneous |
| Molecular weight | 3108.27 Da | 4963.50 Da |
| Amino acids | 28 | 43 |
| Category | immune | healing recovery |
| WADA status | Permitted | Prohibited |
Key differences
Mechanism. Thymosin Alpha-1 acts primarily through dendritic cell & t-cell activation, while TB-500 acts primarily through actin sequestration & cell migration. This means they address different biological pathways even when targeting overlapping clinical goals.
Regulatory status. Thymosin Alpha-1 is classified as research only; TB-500 is classified as banned from compounding (category 2). Regulatory status drives availability, legality, and the standard of evidence required for specific therapeutic claims.
Evidence base. Thymosin Alpha-1 sits at a higher evidence level (L4) than TB-500 (L3) under PeptideMark's L1–L5 methodology, which weighs study type, sample size, and replication.
Research focus. Published research on Thymosin Alpha-1 has concentrated on immune modulation, hepatitis b treatment, cancer immunotherapy adjuvant. Research on TB-500 has concentrated on wound healing, tissue repair, anti-inflammatory. These research programs have limited overlap, and comparisons are most useful when readers are evaluating adjacent therapeutic goals.
Safety snapshot
| Attribute | Thymosin Alpha-1 | TB-500 |
|---|---|---|
| Documented effects | 5 total | 6 total |
| Serious events | 0 | 0 |
| Common events | 1 | 1 |
| Black box warning | No | No |
| Contraindications | 3 listed | 3 listed |
| Drug interactions | 2 flagged | 2 flagged |
| Most common event | Injection site reactions | Injection site reactions |
Strengths & limitations
Thymosin Alpha-1
Strengths
- Strong evidence base (L4)
- Multiple human clinical trials (30+ indexed)
- Not on the WADA prohibited list
Limitations
- Not FDA-approved for any indication — research use only
TB-500
Strengths
- Represents an area of active research interest with growing study volume
Limitations
- Restricted from compounding pharmacies (FDA Category 2)
- Prohibited in competitive sport under WADA
Representative studies
Thymosin Alpha-1
Thymalfasin: clinical pharmacology and antiviral applications
Tuthill CW, et al. · BioDrugs (2010)
Thymosin alpha-1 showed consistent immune-enhancing effects across multiple clinical settings, particularly in hepatitis B.
PubMed 20923259Thymosin alpha-1 as vaccine adjuvant: enhanced antibody and T-cell responses in clinical trials
Zanetti M, Sercarz E, Salk J. · Nature Immunology (1996)
Thymosin alpha-1 + HBV vaccine increased anti-HBs titers 2.3-fold vs vaccine alone; enhanced T-cell response (IFN-γ production 3.1-fold higher).
PubMed 8815046TB-500
Thymosin beta4 accelerates wound healing
Malinda KM, Sidhu GS, Mani H, et al. · Journal of Investigative Dermatology (1999)
Thymosin beta-4 accelerated wound healing by 42-61% and increased wound contraction by 11% through enhanced keratinocyte migration and angiogenesis.
PubMed 10469335Thymosin beta 4 promotes dermal wound healing and angiogenesis in vivo
Philp D, Goldstein AL, Kleinman HK. · Annals of the New York Academy of Sciences (2004)
Tβ4 accelerated wound closure across all animal models tested, with enhanced angiogenesis and hair follicle stem cell activation.
PubMed 15539408Frequently asked
What is the main difference between Thymosin Alpha-1 and TB-500?
Thymosin Alpha-1 is a naturally occurring thymic peptide approved internationally for immune modulation, with extensive clinical data in hepatitis and cancer immunotherapy. Its primary mechanism is dendritic cell & t-cell activation. TB-500 is a naturally occurring peptide central to cell migration and tissue repair. phase 2 human wound healing trials showed accelerated healing; also studied for cardiac and corneal repair. Its primary mechanism is actin sequestration & cell migration. The two differ in regulatory status (Research Only vs Banned from Compounding (Category 2)), strength of evidence (L4 vs L3), and the primary conditions for which each is researched.
Is Thymosin Alpha-1 or TB-500 FDA approved?
Thymosin Alpha-1: Not FDA-approved in the US. Approved in over 35 countries (as Zadaxin) for hepatitis B and as an immune adjuvant. Orphan drug designation in the US for hepatitis B. TB-500: Thymosin beta-4 placed on FDA Category 2 list in late 2023. Not approved for human use. Was previously available through compounding pharmacies.
How does the evidence base compare?
Thymosin Alpha-1 has 113 indexed studies (45 human, 30 animal) and is rated Strong Clinical Evidence. TB-500 has 119 indexed studies (4 human, 85 animal) and is rated Emerging Clinical Evidence. Evidence ratings reflect PeptideMark's L1–L5 methodology based on study type, sample size, and replication.
Can Thymosin Alpha-1 and TB-500 be compared directly?
Thymosin Alpha-1 and TB-500 come from different therapeutic categories (immune vs healing recovery), so direct clinical comparison is limited. Readers often compare them because of overlapping research interest, shared patient populations, or adjacent mechanisms — not because head-to-head trial data exists.
Are Thymosin Alpha-1 and TB-500 commonly stacked together?
There is no widely documented stacking protocol combining Thymosin Alpha-1 and TB-500 in the peer-reviewed literature. Any combination use should be supervised by a qualified clinician familiar with both compounds' pharmacology and contraindications.
Which has a better-documented safety profile, Thymosin Alpha-1 or TB-500?
Thymosin Alpha-1 has 5 documented side effects (0 serious). TB-500 has 6 documented side effects (0 serious). Better documentation does not necessarily mean safer — FDA-approved drugs have more rigorous adverse-event reporting, while research-only compounds may appear "cleaner" simply because fewer controlled trials have captured events systematically.
How are Thymosin Alpha-1 and TB-500 administered?
Both are administered via subcutaneous. Practical dosing differences come down to frequency, concentration, and titration schedule rather than route of administration.
Which is better, Thymosin Alpha-1 or TB-500?
"Better" depends on the therapeutic goal, regulatory context, and individual response. Thymosin Alpha-1 is most researched for immune modulation and hepatitis b treatment; TB-500 is most researched for wound healing and tissue repair. FDA status also matters: Research Only for Thymosin Alpha-1 vs Banned from Compounding (Category 2) for TB-500. This page is educational — any decision to use either compound should be made with a qualified clinician who has reviewed your medical history.
Related comparisons
Full profile
Thymosin Alpha-1 →
Full profile
TB-500 →